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To predict Results of Breast Cancer Therapy 
Anna Nordenskjöld 
Department of Oncology, Institute of Clinical Sciences 
Sahlgrenska Academy, University of Gothenburg 
Gothenburg, Sweden 
ABSTRACT 
We have used the almost complete national Swedish Cancer register, regional quality 
management register and one randomized adjuvant endocrine trial to study, the effect of 
radiotherapy in breast cancer with 1-3 positive nodes (study 1), the effect of tamoxifen in 
estrogen receptor (ER)-positive tumors depending on expression of the progesterone receptor 
(PR) (studies 2 and 4) and the development of the survival rates of breast cancer in Sweden 
1989-2013 (study 3). 
Study 1. We compared relative breast cancer survival in two Swedish health care regions that 
between 1989 and 2006 had different guidelines for postoperative radiotherapy. Patients with 
1–3 positive lymph nodes in the western region received radiotherapy of the remaining parts 
of the breast only, while patients in the south eastern region also received therapy of regional 
lymph nodes. Other aspects of the guidelines were very similar including those for screening 
mammography, surgery and adjuvant medical treatment. Results: The 10-year relative 
survival for patients with 1–3 positive lymph nodes was 78% in the western region and 77% in 
the southeastern region (p=0.12). Conclusions: There was little or no influence of addition of 
lymph node radiotherapy on survival in patients with 1–3 positive lymph nodes in a population 
with screening mammography and modern systemic treatment.  
Studies 2 and 4 We investigated the independent predictive value of progesterone receptor 
(PR) determined with immunohistochemistry (IHC) in estrogen receptor (ER) positive tumors 
from patients participating in the Stockholm trial of adjuvant tamoxifen.  Methods We 
evaluated patients without lymph node metastasis for whom PR in study 2 was determined by 
IHC in tissue micro arrays (thin cores of tumor tissue). In study 4, PR was scored by gene 
expression and by IHC of entire tumor sections and separate analyses of patients with luminal 
A tumors were performed. Conclusions PR positivity determined by IHC or gene expression 
is a marker indicating long-term benefit from adjuvant tamoxifen. We observed a very marked 
benefit for patients with PR positive luminal A tumors. 
Study 3 During the recent decades, breast cancer survival has gradually improved but there 
is limited knowledge on the improvement in population-based studies of patients diagnosed 
with different stages of disease and in different age groups. Patients and methods. In two 
Swedish health care regions a total of 42 220 female breast cancer patients below 90 years of 
age were diagnosed between 1989 and 2013. Results. Using patients diagnosed 1989-1993 
as a reference the relative risk of 5 year mortality decreased with 49% (ci95% 45 – 58) for 
patients diagnosed in the end of the observation period. Conclusions.  Improvements were 
seen in all age groups but was unevenly distributed between stages and age groups pointing 
to the need for further improvements for younger and elderly patients. 
Conclusions in summary: In a population invited to mammography, regional radiotherapy in 
patients with breast cancer and 1-3 positive nodes seems to result in little or no influence in 
survival. Expression of PR seems to indicate better long-term effect of tamoxifen in ER-positive 
tumors. The 5-year mortality in breast cancer has been halved in southeast and western 
Sweden between 1989-2013. 
Keywords: Breast cancer, survival, endocrine therapy 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
ARBETE 1 
Syfte Att jämföra överlevnaden i bröstcancer i två regioner i Sverige med olika strålbehandling 
av patienter med en till tre dottersvulster i armhålan. Metoder Mellan 1989 och 2006 
behandlades patienterna mycket lika i den västra och sydöstra sjukvårdsregionen, förutom 
gällande strålbehandling. I den sydöstra regionen erhöll nästan alla patienter strålbehandling 
av operationsområdet och närliggande körtelområde efter bortoperation av bröstet medan ett 
fåtal av patienterna i den västra sjukvårdsregionen strålades. De patienter som erhöll 
bröstbevarande kirurgi fick mer omfattande strålbehandling i sydöstra regionen. Resultat 77% 
av patienterna i sydöstra regionen överlevde i 10 år jämfört med 78% i västra regionen. 
Slutsats Strålbehandling av lymfkörtlar och operationsområde påverkade inte överlevnaden 
hos patienter med en till tre metastaser i armhålan. 
ARBETE 2 OCH 4  
Syfte Att undersöka om tumörernas innehåll av progesteronreceptor kan förutsäga nyttan av 
förebyggande behandling med antiöstrogentabletter. Metoder En studie som genomfördes 
mellan 1976 och 1990 jämförde förebyggande antiöstrogenbehandling med kontroll. Från 
denna studie utvärderade vi 618 patienter med bröstcancer utan dottersvulster i armhålan vars 
cancer innehöll receptor för östrogen. I millimetertjocka kolvar från patienternas bortopererade 
tumörer synliggjordes i mikroskop med hjälp av antikroppar tumörcellernas innehåll av 
progesteronreceptor. I arbete 4 valde vi 582 patienter och studerade progesteronreceptorn i 
hela tvärsnitt av tumörerna. Vi mätte även uttryck av genen för receptorn samt utförde separata 
analyser av den undergrupp av bröstcancer som kallas luminal A. Resultat Patienter vilka 
hade progesteronreceptor i tumörerna eller uttryckte genen för receptorn hade mångårig nytta 
av antiöstrogenbehandling, medan nyttan var mer begränsad då progesteronreceptor inte 
kunde påvisas. Våra resultat visar också på mycket god effekt av antiöstrogenbehandling på 
luminal A tumörer med båda receptorerna. Slutsats Närvaro av progesteronreceptor eller dess 
genuttryck i bröstcancer visar på långvarig nytta av antiöstrogenbehandling. 
ARBETE 3  
Syfte Att undersöka om senare års förbättringar av överlevnaden bland bröstcancerpatienter 
gäller för patienter i alla åldrar och sjukdomsstadier. Metoder Vi studerade 42 220 kvinnliga 
bröstcancerpatienter som insjuknat mellan 1989 och 2013 i sydöstra respektive västra 
sjukhusområdet. De behandlades i enlighet med nationella och regionala riktlinjer.  
Resultat och slutsats Under tidsperioden 1989-2013 minskade risken för bröstcancerdöd 
med 49%. Förbättringar sågs i alla åldersgrupper men var ojämnt fördelad mellan olika stadier 
och åldersgrupper. Vi uppmärksammar behovet av ytterligare förbättringar främst för de yngsta 
och äldsta patienterna.   
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ABBREVIATIONS 
 
AIs=aromatase inhibitors 
ALNI= axillary lymph node involvement 
BCS=breast conserving surgery 
BCM=breast cancer mortality 
CI=confidence interval 
CMF=cyclophosphamide, methotrexate, fluorouracil 
CYP450 enzymes=cytochrome P 450 enzymes 
DCIS=ductal cancer in situ 
DFS=disease free survival 
DMFS=distant metastasis-free survival 
EBCTCG= Early Breast Cancer Trialists’ Collaborative Group 
ER=estrogen receptor 
FFPE=formalin fixed paraffin embedded 
GnRH=gonadotropin releasing hormone 
HER2=human epidermal growth factor receptor 2 
HG=histologic grade 
HR=hazard ratio 
IHC= immunohistochemistry 
ISH=in situ hybridization 
Ki 67=proliferation associated antigen 
LBA=ligand-binding assay 
mAB= monoclonal antibody 
NHG=Nottingham histologic grade 
OFS= ovarian function suppression 
OS=overall survival 
PR= progesterone receptor 
RFS=recurrence free survival 
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RR= recurrence rate 
SCR=Swedish cancer register  
SERM=selective estrogen receptor modulator 
SNOMED= systematized nomenclature of medicine 
STEPP= subpopulation treatment effect pattern plots 
TMA=tissue microarray  
TNM=tumor node metastasis 
TNBC=triple negative breast cancer 
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1 BREAST CANCER- BACKGROUND 
1.1 EPIDEMIOLOGY 
Breast cancer is the most common cancer in women and the second most common cancer 
overall with 1.67 million new breast cancer cases globally in 20121,2. It has been estimated that 
about one in ten women will be affected by breast cancer. The incidence of breast cancer 
standardized by age has gradually increased. In Sweden, the increase for the last twenty years 
is 1.2 per cent per year3. 
However, while the incidence has gradually increased in the Nordic countries, mortality has as 
shown in figure 1 slowly decreased. The reasons for the marked decrease in the proportion of 
fatal breast cancer patients are several including earlier diagnosis and improved therapy. 
 
 
 
 
Figure 1 Breast cancer incidence (red) and mortality (green). Age standardization according 
to the nordic standardpopulation of the year 2000: NORDCAN4 .  
 
 
 
 
 12 
1.2 DIAGNOSIS  
 
Patients seek help from the health care system with a lump or other symptoms such as 
secretion, redness or deformation of the breast. Any such symptoms from the breast should 
be referred to a specialized unit with no delay. There the breast should be investigated with a 
triple diagnostic procedure, including palpation, mammography (often combined with 
ultrasound and sometimes breast magnetic resonance imaging) and fine needle cytology or 
core biopsy. Patients may also be referred to specialized breast units for triple diagnostics 
following a suspicious finding at mammography screening. 
The radiological examinations should be performed before the biopsy. A lobular cancer can 
be difficult to detect with mammography and cytology. Therefore, a diagnostic resection should 
be considered when radiology and cytology do not correlate with symptoms and the findings 
from physical examination. 
Finally, the diagnosis is established with microscopy of either a fine needle aspirate or a 
histologic specimen.  
In Sweden, it has been compulsory since 1958 for both the treating physician and the 
pathologist/cytologist to independently notify the Swedish cancer register (SCR) of all new 
incidences of cancer. The SCR receives reports containing the ICD code of the malignancy, 
the histological systematized nomenclature of medicine (SNOMED) code, the TNM stage of 
the disease, the date of diagnosis, the date of birth for the patient, and the personal 
identification number unique to each individual in Sweden. The completeness of the national 
register is about 96%5. The majority of the patients are also regionally registered in a quality-
management register. These registers contain more detailed information of incident tumor 
characteristics and primary treatment. For breast cancer, >95% of the patients are treated 
according to the management programs and registered in the regional quality-management 
register databases associated with the programs6.  
 
1.3 SCREENING 
 
During the nineteen seventies several randomized trials were initiated in Sweden to investigate 
the ability of mammography screening to reduce mortality from breast cancer. The results 
demonstrated a significant reduction of breast cancer mortality in persons randomized to 
mammography7. Therefore, nationwide mammography screening was introduced in the late 
eighties and the National Board of Health and Welfare (Socialstyrelsen) now recommends 
women between 40 and 74 years to participate. All Nordic countries have now introduced 
mammography screening. Denmark was last to introduce it in 2009 partly as an effort to 
improve breast cancer survival rates that since many years were inferior to those reported from 
other Nordic countries and similar to corresponding unfavorable data from Great Britain8. 
 
With the introduction of screening, the distribution of the biologic subtypes of breast cancer 
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shifted, and overall incidence increased by approximately 10%9. Decades later, this increased 
age-adjusted incidence of breast cancer has remained high10. The bulk of this increase has 
been the early stage breast cancers, suggesting that screening contributes disproportionately 
to the diagnosis of biologically more indolent forms of breast cancer11,12. While screening is 
associated with a relative mortality reduction of 20%7,13, it has increased the diagnosis of low 
risk lesions and contributes to overtreatment 10,11,14,15. In Sweden, in 2017, two thirds of the  
breast cancers in patients aged 40-74 years were detected by screening16. 
 
1.4 PATHOLOGY  
  
The surgical breast cancer specimen and axillary lymph nodes are assessed and classified 
histologically according to the World Health Organization (WHO) classification system from 
200317. The majority of invasive breast cancers are ductal carcinomas (80-90%). About 10% 
are classified as lobular carcinoma with no tendency to form ductal structures. Besides defining 
the tumor as malignant, the pathologist provides prognostic information by performing 
histological grading as described by Bloom and Richardson in 195718 and later revised by 
Elston and Ellis in 199119. This grading system (BRE) contains assessments of the 
components; tubular formation, nuclear atypia and number of mitoses, where all the 
components are given scores from one to three. A total ranking of three-to nine is then 
determined with nine as the most malignant grade. A ranking 3-5 is classified as grade 1, 6 
and 7 as grade 2 and 8 or 9 as grade 3. Currently pathologists also stain breast cancer surgical 
specimens for the Ki 67 antigen as a measure of cancer cell replication, receptors for estrogen 
and progesterone indicating hormone dependence and also the HER2 surface antigen for 
information on sensitivity to anti HER2 therapy. For modern pathology IHC is a very important 
tool and also used as described below in this thesis using formalin fixed tumors. The IHC 
procedure allows the qualitative identification by light microscopy of antigens in sections of 
formalin fixed, paraffin-embedded tissue, via sequential steps with interposed washing steps.  
Prior to staining, endogenous peroxidase activity is blocked and sections are subjected to 
epitope retrieval. The section is subsequently incubated with the primary antibody. A biotin-
conjugated secondary antibody formulation that recognizes in our case mouse 
immunoglobulins is used to detect the primary antibody. A streptavidin-peroxidase conjugate 
is then applied and binds to the biotin present on the secondary antibody. Sections are further 
incubated with the substrate/ chromogen, 3,3’ - diaminobenzidine (DAB), and DAB Substrate 
Buffer. Reaction with the peroxidase produces a visible brown precipitate at the antigen site. 
Sections are counterstained with hematoxylin and coverslipped. Results are interpreted using 
a light microscope.  
Molecular pathology with gene expression profiling is not yet included in Swedish standard 
care but has in clinical trials allowed subgroups of breast cancers to be correlated to prognosis 
and treatment response20-23. When gene expression profiling is used messenger-RNA is 
extracted from the tumor and the enzyme reverse transcriptase is used to copy the mRNA into 
stable double stranded-cDNA. The cDNA is fragmented and fluorescently labelled. The 
labelled fragments bind to an ordered array of complementary oligonucleotides, 
and measurement of fluorescent intensity across the array indicates the abundance of a 
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predetermined set of sequences. These sequences are typically specifically chosen to report 
on genes of interest within the tumor. Based on gene expression, eventually four groups of 
breast cancer have emerged: luminal A, luminal B, HER2 and triple negative. The concordance 
between molecular subtypes measured by gene expression and estimated from the IHC 
staining described above  is relatively high (75-90%)23. The use of the following IHC markers 
to determine molecular subtype has therefore been suggested according to St Gallen 
International Expert Consensus 201124 as described in the table 1 and figure 2 below from the 
Swedish national guideline. 
  Table 1 Breast cancer subtypes according to the St Gallen expert consensus guidelines24                                                                                                                                                                                                                                                                    
Type ER PR HER2 Ki67 
Luminal A ERpos PRpos or neg HER2neg Low Ki67 
Luminal B ERpos and/or PRpos 
HER2+ with 
any Ki67 
High Ki67 
HER2 ERneg PRneg HER2pos  
Triple 
negative 
ERneg PRneg HER2neg  
 
Figure 2 Breast cancer subtypes according to the Swedish national guidelines25, which follows 
definition of subtypes by Maisonneuve et al26 
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1.5 STAGES OF BREAST CANCER 
 
Breast cancer is commonly further described according to the TNM system (Tumor, Node, 
Metastasis) where the local and distant extent of the disease is numerically defined and divided 
to stages I-IV27. Accurate definitive staging is based on pathology reports. Such staging is 
referred to as Pathology TNM or pTNM as illustrated below. 
Stage 0 or carcinoma in situ means that the cancer only grows in the cell layers where it started 
and has not yet penetrated the basal membrane. This is a very early stage that can be 
considered as a precursor of breast cancer, where 20-30 % may develop invasive breast 
cancer. 
Stage I means that the tumor is up to two centimeters in diameter, and has not spread to the 
axillary lymph nodes and is referred to as T1N0M0. 
Stage II compromises tumors that are two to five centimeters in diameter without nodal 
involvement (T2N0M0) or tumors  five centimeters or less that have spread to less than four 
axillary lymph nodes (T1N1M0) or (T2N1M0). 
Stage III intends tumors larger than five centimeters (T3N0M0), or lymph node involvement of 
more than three lymph nodes (T1-T3, N2M0). 
Stage IV means that the cancer has metastasized locally or to other parts of the body (M1). 
Lymph nodes are classified as positive with metastasis if the metastasis is more than two 
millimeters in size. N1 indicates one to three positive axillary lymph nodes, N2 4-9 positive 
axillary lymph nodes and N3, ten and more positive axillary lymph nodes or ipsilateral 
supraclavicular lymph nodes. 
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Table 2 illustrating breast cancer stages27 
Stage 0 Tis N0 M0 
Stage 1A T1 N0 M0 
Stage 1B T0 Nmi M0 
Stage 1B T1 Nmi M0 
Stage 2A T0 N1 M0 
Stage 2A T1 N1 M0 
Stage 2A T2 N0 M0 
Stage 2B T2 N1 M0 
Stage 2B T3 N0 M0 
Stage 3A T0 N2 M0 
Stage 3A T1 N2 M0 
Stage 3A T2 N2 M0 
Stage 3A T3 N1 M0 
Stage 3A T3 N2 M0 
Stage 3B T4 N0 M0 
Stage 3B T4 N1 M0 
Stage 3B T4 N2 M0 
Stage 3C Any T N3 M0 
Stage IV Any T Any N M1 
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1.6 TREATMENT 
 
Nearly all the newly diagnosed breast cancer patients are offered therapy with curative 
intention but approximately 20 % of the patients will despite this develop metastatic disease. 
Distant metastatic disease cannot yet be cured but treated with the intention to relieve 
symptoms and prolong life for months or many times for years. 
Surgery is the main curative treatment in most breast cancer cases. In the early 70s 
mastectomy was the standard operation28. The tumor size, the localization of the tumor, and 
the possibility of nodal involvement are taken into consideration in the choice of surgical extent. 
The options are complete mastectomy or breast-conserving surgery. Several prospective 
randomized studies have compared complete mastectomy with partial mastectomy followed 
by breast radiotherapy, showing no difference in survival between the two techniques29-
32.Therefore in the early 80s breast-conserving surgery became more common28, and the use 
of adjuvant postoperative radiation therapy increased. In situations when mastectomy is 
needed, it may lead to long lasting psychosocial problems33-35. To lessen these problems 
immediate reconstruction with oncoplastic surgery or later breast reconstruction have become 
more common36. Aesthetically successful breast conserving surgery was reported to yield high 
quality of life scores37. 
During the last two decades sentinel node surgery was established as a safe technique to 
investigate the axilla. No difference in the overall survival, disease-free survival or in regional 
control was found when sentinel node biopsy was compared with conventional axillary 
dissection38. Since the sentinel node technique is associated with fewer complications39-41 such 
as arm edema; it is now considered standard care of treatment.  
 
Radiotherapy of breast cancer was introduced more than 100 years ago when it was 
demonstrated that breast cancer was relatively sensitive to radiation. It was first introduced for 
palliation but soon also for postoperative therapy to reduce recurrence rates42. Radiotherapy 
after mastectomy became a common treatment of early breast cancer. This remained until the 
1970s28,43-45. As described below, breast-conserving surgery with radiotherapy and other 
adjuvant therapies later became common. 
Postoperative radiotherapy is currently recommended for patients with a risk of local 
recurrence of more than 20 per cent in ten years. Radiotherapy of the preserved breast is 
offered to patients after breast-conserving surgery 46, and patients operated with mastectomy 
receive radiotherapy of the chest wall and of axillary lymph nodes if the tumor is more than 50 
mm in size, or there is significant lymph node involvement in the surgical specimen25.  
Early side effects of radiotherapy, defined as occurring up to three months after termination of 
radiotherapy, are erythema and pneumonitis47,48.  Later the skin may become more fibrotic and 
stiff49-51. Lymphedema of the arm can also be seen as a late side effect of radiotherapy with 
chronic swelling of the arm. Arm swelling is handicapping and difficult to treat but promising 
results with liposuction were reported52. Other more uncommon late side effects, are late 
appearing pneumonitis, pulmonary fibrosis, rib fractures, secondary malignancies and brachial 
plexus neuropathy53,54. 
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Late side effect from radiotherapy revised from Dan Lundstedt55 
Variable 
Axillary dissection and RT 
No. (%) 
RR (ci 95%) 
Axillary dissection no RT 
No. (%) 
RR (ci 95%) 
Paraesthesia in the hand 
38/192 (19.8) 
1.47 (1.02–2.11) 
68/505 (13,5) 
1.00 (Reference) 
Oedema of the hand 
43/192 (22.4) 
1.46 (1.04–2.03) 
78/507 (15.4) 
1.00 (Reference) 
Pain in the arm 
38/192 (19.8) 
1.02 (0.73-1.42) 
98/504 (19.4) 
1.00 (Reference) 
Decreased strength in hand 
26/192 (13.5) 
1.47 (0.94-3.47) 
47/509 (9.2) 
1.00 (Reference) 
 
The majority of the node-positive as well as node- negative patients are now offered 
hypofractionated radiotherapy of 40 Gy in 15 fractions based on recent data56.  It has recently 
been shown that partial breast radiation may be equally safe as whole breast radiation for 
women more than fifty years old with small luminal cancers57. The ACOSOG Z1158 (an 
American College of Surgeons Oncology Group study) and the AMAROS59 study (a 
multicentric study by European cancer departments collaborating in the European 
Organisation for Research and Treatment of Cancer, EORTC )  both show that patients with a 
positive sentinel node can safely be spared axillary dissection and receive radiotherapy only, 
with little risk of lymphedema. The AMAROS study showed a significantly lower rate of 
lymphedema at five years in the radiotherapy group as compared to the axillary dissection 
group (11% versus 23% and a p-value of less than 0.0001).  
The Oxford overview has shown that at five years postoperative radiotherapy results in a 
reduction in local recurrences of almost 20% and a 15 year overall mortality reduction of 5%60. 
The conclusion is therefore that for every four local recurrences avoided, one breast cancer 
death is avoided. The effects on recurrences and death were similar for all patients, 
irrespectively of age and tumor characteristics. In the Oxford overview published in 2011 on 
the effect of radiotherapy after breast conserving surgery only, similar effects were found, with 
recurrences reduced by 50%, and breast cancer death rate by 16%61. The absolute reductions 
in recurrences and deaths were greater for node-positive women. Also, among node-negative 
women the absolute recurrence reduction varied according to ER-status, tamoxifen use, and 
extent of surgery, with most benefit found for patients with the largest recurrence risk61. 
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Endocrine therapy was introduced in 1896 when it was shown that oophorectomy had a good 
clinical effect on locally advanced breast cancer in premenopausal women62. 
One risk factor for developing breast cancer is exposure to estrogen. Most invasive breast 
cancers (70%-80%) express the estrogen receptor (ER), and are dependent on estrogen for 
their survival. Response to endocrine treatment tends to improve with increasing proportion of 
ER positive tumor cells and with the homogeneity of the ER staining between cells63,64. In 
clinical practice, a cut-off of 10% positive cells is currently used to classify tumors as ER-
positive. However, a cut-off of 1% is sometimes used in i.e. the US65. Some previous studies 
and data presented in this thesis show that combined ER and PR positivity increase the 
probability of response to endocrine therapy66,67. However, these results contrast to a meta-
analysis by the EBCTCG that did not find that PR positivity independently predicted tamoxifen 
response in ER positive tumors30.                                                                                  
Both estrogen and progesterone receptors are members of the steroid–thyroid hormone– 
retinoid receptor superfamily of ligand-activated nuclear transcription factors68,69. The two most 
common isoforms of progesterone receptors (PR-A and PR-B) can act as homo-or 
hetrodimers70,71. They are transcribed from two different promoters of the same gene on 
human chromosome 11 q22–q2369.                                                                                                                                                                                                                                                                                
In premenopausal patients the ovaries are the main source of estrogen, while in 
postmenopausal women estrogen is predominantly produced by aromatization of the adrenal 
and ovarian androgens in the liver, muscle and fat tissue72. The ER pathway can be targeted 
by inhibiting the receptor with tamoxifen or fulvestrant, or by removing estrogen via 
oophorectomy or Luteinizing hormone releasing hormone agonists (LHRH) in premenopausal 
patients or by aromatase inhibitors (AIs) in postmenopausal patients. 
In humans, tamoxifen has an antiestrogenic effect in some tissues and an estrogenic effect in 
other tissues.  The antiestrogenic effects are most prominent in breast tissue and the vagina, 
where tamoxifen reduces glandular as well as epithelial developement73,74. The antiestrogenic 
effect on breast tissue decreases the risk of primary and contralateral breast cancer75,76. 
Among the antiestrogenic effects of the drug are also vasomotor symptoms, such as hot 
flushes, the most common side effect of tamoxifen. However, in some tissues the estrogenic 
effects of tamoxifen are dependent on menopausal status.  
Among postmenopausal women, estrogenic effects are predominant, in the uterus with an 
increased risk of endometrial cancer, in the heart with decreased risk of coronary events, in 
bone with decreased rate of fractures and in coagulation with doubled risk of thrombosis. In 
premenopausal women tamoxifen is antiestrogenic77-84 generating hot flushes, cold sweats, 
genital itching and pain in intercourse. 
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Side effects revised from the NSABP P-1 Study85. A double blinded prevention trial with five 
years of 20 mg tamoxifen daily for women 35-70 with a quality of life questionary at baseline, 
at 3 months, and then every 6 months until 36 months. Side effect counts when reported 
positive at least one time.   
Side effect Tamoxifen Placebo 
Vaginal discharge 55 % 34 % 
Cold sweats 21 % 15 % 
Genital itching 47% 38 % 
Hot flushes 78 % (severe 30 %) 65 % 
Pain in intercourse (age 35-
49) 
32 % 24 % 
 
Side effects revised from the international multicenter ATLAS-study with patients almost 
always treated with 20 mg per day in five respectively ten years. 
Out of 48064 patients in the group treated for ten years and 46959 patients treated for five 
years from the ATLAS study86 
Deaths Ten years number Five years number event ratio 
Pulmonary embolus 10 8 1.21 (0.48-3.04) 
Endometrial cancer 17 11 1.49 (0.71-3.13) 
 
Disease Ten years number Five years number event ratio 
Contralateral 
breast cancer 
415 460 0.88 (0.77-1.01) 
Endometrial cancer 116 63 1.74 (1.30-2.34) 
Pulmonary embolus 
ever hospitalized or 
leading to death 
41 21 1.87 (1.13-3.07) 
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Aromatase inhibitors (AI) were widely introduced in clinical practice in the 1990s but are only 
effective in postmenopausal patients, since aromatase inhibition does not inhibit ovarian 
estrogen production. In contrast, tamoxifen can be used for all women regardless of 
menopausal status. Tamoxifen or AI adjuvant treatment of ER positive disease can reduce 
breast cancer mortality by 30% during 15 years87  with tamoxifen reducing the event rate from 
4-8% yearly to 2-8% yearly.  
While tamoxifen, AIs and ovarian suppression are currently used in the adjuvant settings, 
additional endocrine therapies are used in metastatic disease. Examples are fulvestrant, a 
pure estrogen antagonist that also down regulates the ER, and synthetic progestins such as 
megestrol acetate. Palbociclib is a CD4/6 inhibitor used in addition to fulvestrant or AI in the 
metastatic setting of hormone receptor positive breast cancer88. In addition, high doses of 
estrogen can be effective in patients, that initially responded to endocrine therapy but later 
became resistant to previous endocrine therapy89. 
 
Chemotherapy became available after World War 2 and around 1960 it became evident that 
three of the early agents cyclophosphamide, methotrexate and fluorouracil could induce short 
lasting tumor shrinkage and palliation. After 60 years of use, cyclophosphamide is still a 
standard drug widely used in the therapy of breast cancer.  
Around 1970 the three agents were combined and polychemotherapy was introduced for 
palliation and soon also for adjuvant treatment. Later several other cytotoxic agents were found 
to be active against breast cancer and epirubicin, paclitaxel, docetaxel, vinorelbine and 
capecitabine are cytotoxic drugs currently used in Sweden. 
 
Targeted therapy aims at specific changes in malignant cells. Genetic changes or their 
corresponding proteins can be targeted with drugs.  
Tamoxifen targeting the estrogen receptor was the first successful targeted therapy in cancer 
and is listed as an essential medicine by the World Health Organization. Tamoxifen is in a 
class of selective estrogen receptor modulators (SERMs), having tissue-dependent as well as 
species-dependent effects. For example, tamoxifen has a pure antiestrogen effect in chicks90.  
 Another well-known targeted therapy is trastuzumab (Herceptin). This drug became 
commonly used around the year 2000. Trastuzumab is a humanized monoclonal antibody 
targeting HER291. Approximately 10% of breast cancer tumors have an amplified HER2 gene 
resulting in a disease with high risk of recurrence and most often resistance to endocrine 
therapy. These patients are candidates for one year of adjuvant trastuzumab therapy25.  
Bisphosphonate treatment targeting osteoclasts is able to reduce skeletal events and reduce 
mortality for high risk postmenopausal breast cancer patients by approximately two per cent 
at ten years92. This is now standard of care25. 
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1.7 ADJUVANT TREATMENT 
 
After the introduction of radical mastectomy more than 100 years ago93, it became evident that 
breast cancer patients in spite of radical surgery carried a substantial risk of developing local 
and distant disease recurrences. Based on this experience, trials of postoperative treatment 
were introduced.  
These are referred to as adjuvant treatment. Based on the marked effect of radiotherapy and 
ovarian ablation for palliative treatment of breast cancer the first trials of adjuvant treatment 
included radiotherapy44,94 or castration95 and later trials with cytotoxic chemotherapy96,97 and 
tamoxifen98,99, were introduced. Highly significant reductions in the annual rates both of 
recurrence and death were produced by radiotherapy, by tamoxifen, by ablation below age 50 
and by polychemotherapy99. Tamoxifen was introduced in the palliative setting during the 
1970s100, and became commonly used in the adjuvant setting in the 1980s101.   
Most current patients with breast cancer are therefore offered adjuvant treatment.  
During the nineteen seventies randomized trials demonstrated that postoperative combination 
chemotherapy with cyclophosphamide, methotrexate and fluorouracil could significantly 
reduce breast cancer mortality 87,102. Later introduced regimens containing the anthracyclines 
doxorubicin or epirubicine87,103 and the taxanes paclitaxel and docetaxel have resulted in 
further prolonged survival104 but also in new types of toxicity such as cardiotoxicity, 
oncogenicity and allergic reactions. Adjuvant chemotherapy is now individualized and more 
toxic combinations are reserved for patients with high-risk disease. That is patients with triple 
negative disease, Her 2 positive tumors larger than 5 mm and luminal B tumors, but also 
luminal A type tumors with extensive lymph node metastasis. For anthracycline-based therapy, 
the acute side effects are nausea, alopecia, vomiting, lack of appetite, sensibility to infections, 
mucositis, acute menopause and fatigue. Anthracycline therapy can also give late side effects 
such as acute myeloid leukemia and heart failure. Toxicities for taxanes are pain in muscles 
and bones, sensibility to infections, neurotoxicity, hypersensitivity reactions and fatigue105. For 
premenopausal patients, chemotherapy may reduce breast cancer mortality by about 40% and 
for postmenopausal patients, this reduction is about 20%87 during 15 years.  
For some patients receiving adjuvant therapy, it is lifesaving. However, for the majority of the 
patients it adds unnecessary risk, trouble and toxicity. Unfortunately, we are unable to precisely 
identify the patients that should survive without adjuvant therapy and those who die from 
cancer in spite of adjuvant therapy. This is an ethically difficult issue that motivated my studies 
to more precisely identify patients benefitting from radiotherapy and adjuvant tamoxifen. It 
needs consideration by those treating cancer and it was discussed by the last St. Gallen 
panel106 recommending breast cancer therapy.  The panel agreed on escalating radiation 
therapy with nodal irradiation in high-risk patients, but was in favor of omission of boost in low-
risk patients. High risk means patients with tumor bigger than 5 centimeters and/or extensive 
lymph node engagement.  The panel recommended Gene expression signatures that permit 
avoidance of chemotherapy in many patients with ER positive breast cancer.  The panel further 
escalated the recommendations for adjuvant treatment for women with high-risk ER positive 
tumors to include ovarian suppression in premenopausal women and extended therapy for 
postmenopausal women. The low-risk patients, however, can avoid these treatments.  
 23 
2 AIMS OF THE STUDY 
 
Adjuvant treatment of breast cancer after radical resection is based on our understanding of 
the prognosis and the predictive information we can obtain from the pathology report and 
staging. Retrospective correlation of overall survival, disease free survival and the 
pretreatment findings are the bases for patient groupings. Randomized trials then give us 
information on the effects of treatment. Based on the interpretation of trial results, international 
and national guidelines are developed, where different subgroups/stages are recommended 
treatment aiming to achieve a well-judged balance of treatment effects versus side effects. 
The overall aim of this thesis is to add knowledge that could improve the selection of patients, 
that is to fine tune treatment. The particular aim includes: 
i) investigating the prognoses of patients diagnosed with different stages of breast 
cancer 
ii) analysis of the benefits from postoperative radiotherapy in stage 2 patients with 1-
3 metastatic axillary lymph nodes and 
iii) analysis of the influence of the progesterone receptor (PR) level on the benefit 
from postoperative tamoxifen therapy.  
The first study focuses on the effect of adjuvant radiotherapy given to patients with one to three 
positive lymph nodes. The hypothesis is: loco-regional radiotherapy given to breast cancer 
patients with 1-3 positive axillary nodes prolongs survival as compared to that of patients 
receiving less or no locoregional radiotherapy. 
The second study compares the benefit from adjuvant tamoxifen in patients with tumors 
positive for both estrogen receptor (ER)and PR with that for patients with tumors positive for 
ER only. The hypothesis is: PR positivity as compared to PR negativity is a marker for 
increased benefit from tamoxifen treatment. 
The aim of the third article was to study the development in breast cancer survival after primary 
diagnosis divided by stage and age. The hypothesis is: the gradual improvement of survival in 
breast cancer is evenly distributed between stages of disease and age groups rather than 
unevenly distributed between stages and age groups. 
The fourth article extends the study in the second article to include tumor content of PR 
estimated by immunohistochemistry in tumor sections and expression of the PR gene. The 
hypothesis is that PR positivity as compared to PR negativity measured with gene expression 
or whole section IHC is a marker for increased benefit from tamoxifen treatment.  
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2.1 STUDY 1 
 
2.1.1 BACKGROUND 
 
The early studies comparing postoperative radiotherapy versus control in patients with lymph 
node positive disease reported unfavorable survival rates in the experimental arms and even 
worse rates in the control arms Overgaard61,107. Overgaard et. al. recruited premenopausal 
patients from 1982 to 1989. The ten year survival was only 54 % in the group that received 
both CMF and radiotherapy. There was a high loco-regional recurrence rate (30%) observed 
in patients with one to three involved nodes. However, only a mean of seven lymph nodes 
were identified in the surgical specimens indicating that some patients had metastatic nodes 
left in the axilla partially explaining the high recurrence rate. In the EBCTCG metaanalysis of 
studies beginning before year 2000 the survival rates are also low61.  For node negative 
patients the risk reduction at 15 years for patients receiving radiotherapy was from 25, 5% to 
21,1% that is 4,4% reduction in breast cancer deaths. The corresponding risk reduction at 15 
years for node positive patients was from 51,3% to 42,8% that is 8,5%.  In our study with more 
modern treatment the relative survival is more than 75% at ten years for the whole cohort. It 
has therefore been questioned whether the early randomized studies are relevant for patients 
participating in mammography screening programs and treated with modern surgery and 
systemic therapy. A survey among European radiation oncologists on the use of post 
mastectomy radiotherapy in women with 1-3 positive nodes showed wide variations among 
those advocating radiotherapy from as little as 19% in Italy and up to 74% in Spain and 
Portugal108. We therefore wanted to provide more modern data from a large cohort on the 
effect of postoperative radiotherapy on survival. 
 
2.1.2 PATIENTS AND METHODS 
 
For our first study we selected patients from two population-based cohorts of all patients 
diagnosed with breast cancer between January 1 1989 and December 31 2006. 18 697 were 
diagnosed in the western heath care region (W-region) and 11 032 in the South Eastern region 
(SE-region). As seen in the figure 4 below, 2750 from the W-region and 1698 from the SE-
region were found to have 1–3 positive axillary lymph nodes in the surgical specimen. To these 
patients postmastectomy radiotherapy was generally given in the southeast region (89% of all 
cases) and generally not given in the west region (15% of all cases). For patients with 1–3 
positive nodes who underwent breast-conserving surgery, patients in the west region had 
breast radiotherapy only, while patients in the southeast region had both breast and lymph 
nodes irradiated. The patients were followed up for vital status until August 2010 through 
record linkage to national population registers.  
We retrieved information from the quality-management registers regarding age at diagnosis; 
type of surgery; tumor size; number of examined nodes; hormone receptor status; grade; and 
adjuvant therapy regarding radiotherapy (Yes/No), endocrine therapy (Yes/No), and 
chemotherapy (Yes/No).  
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Relative survival was computed using the Ederer II method109. Mortality data for the general 
population in Sweden were used to estimate expected survival rates for the study populations. 
The mortality data comprised the probability of death for single-year age groups in 1-year 
calendar periods. Relative risk between different groups was estimated by Poisson regression. 
A p value of <0.05 was considered to be statistically significant.  
 
Figure 4. Consort diagram study 1 We selected patients with one to three positive nodes: 2750 
from the W region and 1698 from the SE region, both representing 15% of the respective total 
populations as illustrated. All registered incident breast cancer cases in the Swedish Cancer 
Register from these two regions from 1989 to 2006 comprised the initial study base. From the 
total cases, all primary operated cases without initial distant metastases and age <75 years 
with one to three positive lymph nodes were selected.  
 
2.1.3 RESULTS AND DISCUSSION 
 
The 10-year relative survival for patients with 1–3 positive lymph nodes was 78% in the west 
region and 77% in the southeast region (p=0.12).  
Separate analyses depending on type of surgery, as well as number of examined nodes, also 
revealed no significant differences in relative survival rates.  
In the cancer register 
diagnosed 1989-2006
Western South-East
18697 11032
In the regional 
breast cancer register
Western South-East
17526 10840
Primary operated and
no distant metastases
Western South-East
15802 10080
<75 years old
Western South-East
12635 8101
Not registrated in the regional 
breast cancer register 
Western South-East
1171 192
Not primary operated or
distant metastases
Western South-East
1724 760
Breast surgery not specified
Western South-East
3 9
≥75 years old
Western South-East
3167 1979
No lymph node metastases
Western South-East
8338 5464
>3 lymph node metastases
Western South-East
1544 930
1 -3 lymph node metastases
Western South-East
2753 1707
Excluded
Breast surgery
Western South-East
2750 1698
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The survival rate in this study of Swedish cohorts with 1–3 positive nodes is similar to t that of 
groups without lymph node involvement in the EBCTCG analysis, in which no apparent effect 
on breast cancer specific survival was seen for postmastectomy radiotherapy61. 
One reason that the effect of radiotherapy was not detected in this cohort study is that the 
survival rates are high in both cohorts. These data need to be interpreted with caution, the first 
conclusion that radiotherapy has no effect on the survival of patients with high survival rates is 
not justified. Indeed, it has been demonstrated that postoperative radiotherapy effectively 
reduces local recurrence rates and that approximately 25% of the local recurrences result in 
breast cancer specific mortality. In a nonrandomized study like ours, there certainly are minor 
differences between the groups that may affect outcome. Differences that we detected were 
that in the western region there were more lymph nodes removed and more cytotoxic agents 
given as compared to the south-eastern region, where more endocrine therapy was given.  
Our major conclusion is that in a mammography screened population receiving modern 
surgery and adjuvant therapy, the presence of 1-3 involved node in the surgical specimen does 
not strongly motivate postoperative radiotherapy. Other indicators must also be considered. 
 
 
2.2 STUDIES 2 AND 4 
 
2.2.1 BACKGROUND 
 
The independent predictive information from progesterone receptor (PR) positivity for breast 
cancer treated with tamoxifen has been questioned after an overview by the Early Breast 
Cancer Trialists’ Collaborative Group (EBCTCG). However, most studies in the overview were 
performed with different cytosol assays before modern PR immunohistochemistry (IHC) was 
developed75. We therefore decided to analyze PR with more modern techniques. 
In study 2 we investigated the predictive value of PR determined with IHC in tissue micro arrays 
from estrogen receptor (ER)-positive tumors from patients participating in the Stockholm trial 
of adjuvant tamoxifen therapy. A second aim was to investigate if the effect varies over time 
and/or with increased levels of PR positivity. See figure 5 left flow-chart.  
 
2.2.2  PATIENTS AND METHODS 
 
In study 2 the IHC staining was performed using the Ventana HX automatic system BenchMark 
(Ventana Medical System, SA IllKirch, Cedex, France). Primary monoclonal anti- bodies were 
the CONFIRMTM mouse anti-ER antibody (clone 6F11) and the CONFIRMTM mouse anti-PR 
anti- body (clone 16) from Ventana Medical Systems. Antigen retrieval and staining procedure 
were performed according to the instruction by the Ventana manufacture. Positive controls 
were run with each batch. Only the invasive part of the carcinoma was assessed, and for each 
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case, all three cores of the TMA were reviewed. The receptor levels presented are based on 
an average of the three cores of the TMA. The proportion of stained nuclei was recorded as 0, 
1–9 %, 10–24 %, 25–49 %, 50–74 %, 75–89 %, and >90 %. The scoring was done by two 
pathologists Lambert Skoog and Britta Löfdahl. 
To compare the association between PR expression and clinical parameters, the Pearson chi-
squared test (categorical variables) and the Student’s t-test (continuous variables) were 
applied. 
Cumulative recurrence risk, cumulative distant recurrence risk and for cumulative breast 
cancer specific mortality were estimated by the Kaplan-Meier method. Hazard ratios (HR) and 
95% confidence intervals were estimated using the Cox’s proportional hazards model. When 
we investigated the influence of different levels of PR positivity on recurrence free survival 
Helena Fohlin, expert statistician and shared first author, performed subpopulation treatment 
effect pattern plots (STEPP) 
STEPP is an exploratory technique for graphical testing of interactions between treatment and 
continuous covariables. It considers sequences of potentially overlapping subpopulations 
defined with respect to covariate and is especially useful when trying to identify subpopulations 
of patients for whom the overall results may be less representative. There are several 
advantages of the method, e.g., that no assumption about the nature of the relationship 
between the outcome and the covariate in each treatment group must be done and that is 
avoids dichotomization of co-variables, which may be subjective. Though, the size of the 
subpopulations is critical to the performance of the method and, hence, to the interpretation of 
the results110,111. In study 2 we used STEPP to investigate the interaction between continuous 
PR values and the effect of tamoxifen. To avoid results based on one single subgroup division, 
we performed the STEPP analysis with different numbers of subgroups and ensured that the 
achieved results were similar independently of the chosen number of subgroups. 
In study 4 of 582 patients with ER positive tumors, we included PR IHC of whole tumor 
sections, PR H-scoring, PR scored by gene expression, and subanalyses of patients with 
luminal A subtype tumors. See figure 5 right. 
In 2014, immunohistochemistry (ER, progesterone receptor [PR], human epidermal growth 
factor receptor 2 [HER2], and Ki-67) was performed on 727 patient whole-tumor sections in a 
random order at a single medical CLIA laboratory (University of California Davis Medical 
Center, UCDMC). The FFPE tumors were sectioned at 5 microns and mounted on plus coated 
glass slides in the Tissue Profiling Facility at the Science for Life Laboratory in Uppsala 
University. The slides were stained in the UCDMC IHC laboratory using DAKO Link48 
Autostainer. Antibodies used were: ER (SP1; Spring Bioscience M301), PR (PgR 636; DAKO 
IR068), HER2 (HercepTest; DAKO SK001), and Ki67 (MIB-1; DAKO M7240). EnVision+ 
detection was used, following standard recommended procedures and with per-run positive 
controls assessed by quantitative image analysis to ensure consistent run-to-run staining 
intensity.    
Pathologists at the University of California with expertise in breast diagnostics, as a part of the 
ATHENA Breast Health network, scored the percentage of positive breast cancer cells for each 
ER and PR intensity level (0, +1, +2 or +3) compared to established standards. In addition, the 
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percentage of positive cancer cells for HER2 and Ki-67 were also scored. We computed the 
total percentage of cells stained positive for ER and for PR (at intensity levels +1, +2 and +3) 
and the ER and PR H-score defined as the sum of the percent of positive tumor cells at each 
intensity level multiplied by an ordinal value corresponding to the intensity level (0=none, 
1=weak, 2=moderate, and 3=strong).   
Gene expression data was generated using custom designed Agilent arrays containing 
approximately 32.1K probes, representing approximately 21.5K unique genes from FFPE 
breast cancer tumor tissue. Gene expressions from each chip were log2-scaled and upper 
quartile normalized. In total 652 breast cancer tumors passed the quality check.  
Survival curves were constructed by Kaplan-Meier analyses and differences between groups 
were assessed using the Log-rank test.  
Multivariate analyses of tamoxifen benefit in groups based on PR status were performed using 
Cox proportional hazard modeling adjusting for classical patient and tumor characteristics such 
as age and year of breast cancer diagnosis, HER2 status, Ki-67 status (15% used as positive 
cut-off), tumor grade and tumor size. 
 
Figure 5 Consort diagram from study 2 left and study 4, right 
 
Comments regarding study group selection. For study 2, from November 1976 through June 
1990, 2738 patients entered the Stockholm 3 trial. Among them, 1780 patients (65 %) with no 
lymph node metastases and a tumor diameter of 30 mm or less (established by histological 
examination) were classified as ‘‘low risk’’ and did not receive cytotoxic chemotherapy. In this 
group, 432 patients were treated with breast conserving surgery including axillary dissection 
plus radiation to the breast (50Gy / 5 weeks). The remaining 1348 patients had a modified 
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radical mastectomy and no radiotherapy. From the low-risk patients, we were able to retrieve 
paraffin blocks from 912 for construction of microtissue arrays (TMAs). The trial included 
patients irrespectively of hormone receptor content, but prospectively collected data on ER 
and PR status were available and archived tumor tissue had sufficiently high quality for IHC 
analysis in 795 cases. These patients had similar age distribution, tumors of similar size, and 
proportion of ER-positive tumors as the entire group of 1780 patients with low-risk tumors. The 
proportion of patients randomized to tamoxifen therapy was 52 % as compared to 50 % in the 
entire group. Among the tumors analyzed for PR by IHC, 591 were ER-positive as determined 
by IHC, while 27 tumors with missing data on ER by IHC were ER-positive according to cytosol 
analysis, resulting in 618 ER-positive tumors (Fig. 5 left).  
Study group selection to study 4. The right part of figure 5 illustrates the selection of the subset 
of formalin-fixed paraffin-embedded tumor material available from the same clinical trial and 
used in study 2. This subset was also well balanced to the original STO-3 trial cohort with 
regards to tumor characteristics, such as tumor size (78% vs 81%), ER status (78% vs 80%) 
and treatment arm assignment (52% vs 50%). All patients included in the STO-3 randomized 
trial have detailed patient and clinical information.  
 
2.2.3 RESULTS AND DISCUSSION 
 
Study 2 showed that patients with ER positive tumors that were also PR positive by IHC had 
significantly prolonged recurrence free survival benefit from tamoxifen as compared to those 
with tumors positive for ER only.  
There was no trend indicating more benefit with increasing proportion of stained cells. Results 
from the trial have previously shown a significantly reduced recurrence rate among patients 
with ER-positive tumors randomized to tamoxifen therapy versus control (HR = 0.53 (0.37–
0.74), p< 0.001)112.  
Patients with ER positive as well as PR positive tumors receiving tamoxifen had a reduced 
recurrence risk compared with those who were not treated with tamoxifen (HR = 0.43, 95 % 
CI 0.29–0.62, p< 0.001) For patients with ER positive and PR negative tumors, the effect of 
the treatment was time-dependent. The first 5 years after diagnosis the tamoxifen treated 
patients had a reduced recurrence risk (HR = 0.39, 95 % CI 0.15–1.00, p = 0.05), whereas it 
increased thereafter (HR = 1.34, 95 % CI 0.69–2.60, p = 0.39). Seen over the whole time 
period, the relative risk ratio for tamoxifen treatment versus the control group when comparing 
PR positive and PR negative tumors was 0.49 (95 % CI 0.25–0.92, p = 0.03).  
Study 4 demonstrated that tamoxifen treated patients with ER-positive tumors that were also 
PR-positive by IHC or gene expression had a reduced long term risk to develop metastasis as 
compared to untreated patients with ER and PR positive tumors (PR-positive IHC Hazard ratio 
[HR] = 0.34, 95% confidence interval [CI] 0.21 to 0.56, PR-positive by gene expression HR = 
0.38, 95% CI 0.24 to 0.63. For treated patients with ER-positive but PR-negative tumors by 
IHC or gene expression there was not a significant risk reduction (PR-negative IHC HR = 0·58, 
95% CI 0·32 to 1·06, PR-negative by gene expression HR = 0·61, 95% CI 0·32 to 1·16)) 
compared to untreated patients with the same receptor profile and the risk reduction tended to 
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be limited to the first decade after surgery. We used both metastasis-free survival and breast 
cancer-specific survival as endpoints and they yielded similar results. Two years of tamoxifen 
therapy had a very marked effect on risk of metastasis for patients with ER positive and PR 
positive luminal A tumors as compared to patients in the untreated arm with the same receptor 
pattern (HR = 0.23, 95% CI 0.11 to 0.49).  
One reason that the EBCTCG study does not show any extra benefit from tamoxifen for 
patients with tumors positive for both ER and PR may be that 41% of the patients in the 
overview was additionally treated with cytotoxic agents.  
Another reason may be that the cytosol techniques used in the metaanalysis from the 
EBCTCG was not good enough113.It is stated in the overview that as much as 21% of the ER-
negative cancers were PR-positive indicating that the PR technique used resulted in many 
false positive PR classifications. It has been clearly demonstrated with IHC and gene 
expression assays that PR-positivity and PR gene expression is a rare event only present in 
1-4 % of ER-negative tumors 114. Our data on the increased benefit from tamoxifen therapy for 
patients with both ER and PR positive tumors may be compared to those obtained by Elebro 
et al. demonstrating favorable outcome for patients with ER and androgen receptor (AR) 
positive tumors115,116. A study of the effect of endocrine therapy of patients with triple positive 
(ER+PR+AR) tumors is required. 
 
2.3 STUDY 3 
 
2.3.1 BACKGROUND 
 
Before approximately 1750 when breast surgery was introduced, breast cancer was not 
considered curable. Around 1850 when general anesthesia was available radical mastectomy 
was introduced by Halsted at al 93and local recurrences became less common but long term 
survival was not reported. However, in the 19th century some untreated breast cancer patients 
survived long periods18. From 1960 after the introduction of cancer registration in Sweden we 
have information on population based breast cancer survival and Talbäck et al 117 reported that 
10 year relative survival increased from 53% 1965 to 74% in 1990. In study 3 we report that 
after 1990 survival has further increased. The survival rates had clearly increased for the whole 
group of breast cancer patients but there was limited information on the development of 
survival for patients with different stages of disease. Therefore, we performed study 3 to 
investigate stage specific and age specific survival rates 
As in study 1, relative survival was computed using the Ederer II method109. Age 
standardization was applied according to International Cancer Survival Standard 1 (ICSS 1) 
with the weights 0.04, 0.15, 0.37 and 0.44 for the age groups < 40, 40 – 55, 55 – 69 and ≥ 70, 
respectively. The weights 0.44, 0.22, 0.17, 0.14 and 0.03 were used for the stage 
standardization for stage I, II N0, II N+, III and IV, respectively. Survival time was calculated 
from date of diagnosis to 31 December 2014 or to date of death if it occurred before that date. 
For each stage, excess mortality rate ratio between different calendar periods was estimated 
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using Poisson regression, including the categorical variables year of diagnosis (in groups of 
five calendar years each) and age group.  
2.3.2 RESULTS AND DISCUSSION 
 
Using patients diagnosed 1989-1993 as a reference the relative risk of 5 year mortality 
decreased with 49% for patients diagnosed in the end of the observation period (ci95% 45-
58). The mortality tended to decrease for patients with all stages of breast cancer and test for 
trend resulted in a statistically significant improvement over time in 5 year relative survival in 
stage III and IV and in 10 year survival in stage I and III.  
For each operable stage of disease, patients aged below 40 years or more than 70 years when 
diagnosed tended to have less favorable survival than patients diagnosed between 40-69 
years of age. Test for trend resulted in statistically significant improvements over time for 
patients diagnosed at ages below 40, 40-54 and 54-69 but less marked improvements for 
patients older than 70 when diagnosed. Our data on age related to survival are in line with 
those from Malmö Sweden from a large cohort of single institution patients collected 1961-
1991 mainly before the introduction of mammography screening showing decreased 10 year 
survival for patients below 40 and above 80 as compared to patients 40-49 years of age118. 
Notably, we observed a 40% increase in in breast cancer diagnoses between 1989 and 2013. 
Part of this might be explained by the aging society, as increasing age is a major risk factor for 
breast cancer. Gradually increased participation in mammography screening introduction of 
digital mammography with excellent detection rate and increased use of ultrasound and MR 
for breast examinations may also have contributed to the increased detection rate. Some of 
the increased survival may be explained by an increased lead-time bias by this increased 
detection rate. 
During the two decades of patient recruitment, there has been a gradual development of CT-
scanning, MR and PET technology facilitating the detection of distant metastasis possibly 
resulting in an increased rate of patients with stage IV disease. However, this rate remained 
low around 2.6% during the entire period. Therefore, we think that improved treatment rather 
than stage migration explains the improved five year outcome.  
Moreover, the stage distribution during the time period was relatively stable, which contradicts 
stage migration as a major explanation for the improved relative survival. However, the 
proportion of patients with stage II N+ disease markedly increased with time possibly reflecting 
the improved pathological and radiological techniques available to detect lymph node 
metastases. 
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3 CONCLUSIONS 
 
From study 1 where we investigated relative survival of two cohorts of patients with 1-3 axillary 
node metastasis there are two main findings. The first is that more recent patients with access 
to mammography screening, dedicated breast surgeons and modern adjuvant therapy have 
much improved survival rates as compared to the patients participating in the old trials 
comparing patients treated with regional postoperative radiotherapy with control groups 
without radiotherapy. Therefore, the old trials have limited relevance for current patients with 
1-3 positive nodes. The second conclusion is that with increased survival rates for patients 
with 1-3 positive nodes there is less room for improvements and a possible improvement was 
not detectable by comparison of our two cohorts treated with, respectively without regional 
radiotherapy. Therefore, we conclude that not all patients with 1-3 involved nodes should be 
recommended locoregional radiotherapy. Other risk factors for locoregional recurrence 
including lymphovascular invasion, tumor grade and HER2 status should be considered.  
In papers 2 and 4 we studied the predictive value of PR for the response to tamoxifen in ER 
positive breast cancer. The protein synthesis of PR is known to be dependent of a functioning 
ER119. It is therefore reasonable to speculate that truly estrogen dependent cancers should 
have both receptors to be able to respond to antiestrogen therapy. It was therefore unexpected 
when the EBCTCG overview found the same benefit from adjuvant tamoxifen therapy in 
patients with tumors positive to ER only as for those with tumors positive for both ER and PR. 
Using both immunohistochemistry and gene expression to study PR, we confirm that patients 
with tumors positive for ER only may benefit from adjuvant tamoxifen therapy, but in contrast 
to the findings in the overview patients positive for both receptors tended to have more marked 
and prolonged metastasis free survival rates. Our studies do not have the statistical power to 
convincingly demonstrate a difference in metastasis free survival between patients with tumors 
positive for ER only and patients with tumors positive for both receptors but our data strongly 
indicate more benefit from adjuvant tamoxifen for patients with tumors expressing both 
receptors. We are strongly motivated to continue the studies with more tumors and patients to 
be able to study the issue with more statistical power. 
The third study investigated the development of relative breast cancer survival divided by age 
groups and stages. Using patients diagnosed 1989-1993 as a reference the relative risk of 5 
year mortality decreased with 49% for patients diagnosed in the end of the observation period. 
In fact, breast cancer mortality has gradually decreased since the start of the Swedish cancer 
registry in 1960 and thus continued the years we investigated. The mortality tended to 
decrease for patients with all stages of breast cancer and test for trend resulted in a statistically 
significant improvement over time in 5 year relative survival in stage III and IV and in 10 year 
survival in stage I and III. However, in line with previous observations, patients aged below 40 
years or more than 70 years when diagnosed tended to have less favorable survival than 
patients diagnosed between 40-69 years of age. Also, during the two decades of observation, 
we observed no statistically significant improvement in survival for patients older than 70 years 
at the time of diagnosis. We conclude that there is much room for improvement of care for 
patients below 40 and above 70. 
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4 FUTURE PERSPECTIVES 
 
I would like to contribute to future studies with the following aims: 
1. To investigate the correlation between tumor steroid hormone receptor levels and the 
benefit from endocrine therapy of breast cancer. 
2. To identify gene expression signatures for endocrine therapy benefit 
In Sweden alone one in ten women is diagnosed with breast cancer during her lifetime. Over 
the past decades a gradual increase in survival has been observed due to early detection, 
improved diagnostics and treatment. However, despite the improvements approximately one 
out of four women diagnosed with breast cancer will later develop distant metastatic disease 
and eventually die from breast cancer75,87.  
Breast cancer is a diverse disease with a natural history, occasionally spanning more than 20 
years between primary tumor diagnosis and metastatic disease. We need improved 
procedures to identify patients at high risk for metastatic disease and improved predictors to 
tailor adjuvant and palliative therapy. 
As discussed in this thesis the benefit from adjuvant endocrine therapy depends on the 
expression of the ER and PR receptors. However approximately 50% of the receptor positive 
tumors fail to respond to endocrine therapy.  
 
To be able to contribute to future studies of endocrine therapy I need and want to continue 
fruitful collaboration with my current collaborators including my tutors Per Albertsson and Per 
Karlsson, the Stockholm breast cancer group including Tommy Fornander, Lambert Skoog, 
Linda Lindström and Huma Dar, via Linda also extended to Laura Essermans group in San 
Fransisco, the Linkoping breast cancer research group headed by Olle Stål including Helena 
Fohlin, Johan Rosell and Gizeh Perez Tenorio and the South Swedish breast cancer group 
including Mårten Fernö, Lisa Rydén, Pär-Ola Bendahl and Maria Ekholm. 
 
4.1 RANDOMIZED TRIALS FOR CURRENT AND FUTURE ANALYSES 
 
1. The Swedish breast cancer group comparison of two and five years or adjuvant 
tamoxifen. 
When the study was published in 1996 it showed that five years of treatment resulted in 
prolonged recurrence free survival as compared to two years of treatment. The database for 
this trial is kept at Regional Cancer Center in Linkoping and has been updated by statistician 
Johan Rosell.  We are now, in collaboration with docent Tommy Fornander, professor Mårten 
Fernö, professor Olle Stål and collaborators using this material to investigate the correlation of 
ER and PR receptors with long time recurrence free survival. The study, organized by the 
Swedish breast cancer group, recruited 4610 patients. 2346 were given two years of tamoxifen 
and 2264 five years of therapy. Out of this group were have selected 1691 from the South 
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Eastern region, 1320 from the Southern region and 811 from the Stockholm region for 
analyses. 
2. The Stockholm-3 trial used in our previous work recruited patients between 1976 until 
the end of 1989, randomized to receive tamoxifen versus not.  
Low-risk patients were defined as patients with lymph node-negative disease and a tumor size 
of less than or equal to 3 cm in diameter. All patients included in the trial have detailed patient 
and clinical information along with a complete follow-up of more than 25 years. As described 
in the thesis the trial information is updated to include the standard breast cancer 
immunohistochemical markers (727 patients) namely estrogen receptor (ER), progesterone 
receptor (PR), HER2 and Ki-67 along with information on intra-tumor heterogeneity of these 
markers. Gene expression data was generated using custom designed Agilent arrays 
containing approximately 32.1K probes, representing approximately 21.5K unique genes from 
FFPE breast cancer tumor tissue. Approximately 90% (or 652 breast cancer tumors) passed 
the RNA quality check (according to the diagnostic quality model). This information is available 
and currently used. 
3. The Stockholm-2 trial of high risk patients. 
All patients enrolled in this randomized trial, between 1976 until the end of 1989, received 
chemotherapy or locoregional radiotherapy and patients that were postmenopausal were 
randomized to tamoxifen versus not. High-risk patients were defined as patients with lymph 
node-positive breast cancer and /or/a tumor size exceeding 3 cm. All patients included in the 
trial have detailed patient and clinical information along with a complete follow-up of more than 
25 years. Tumors from the trial are currently collected and updated with standard breast cancer 
markers (ER, PR, HER2 and Ki-67) and intra-tumor heterogeneity of these markers along with 
gene expression data using custom designed Agilent arrays as described above.  
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